Skip to content

In the BioHarmony Drug Report Database

Fondaparinux sodium

Arixtra (fondaparinux sodium) is an oligosaccharide pharmaceutical. Fondaparinux sodium was first approved as Arixtra on 2001-12-07. It is used to treat pulmonary embolism and venous thrombosis in the USA. It has been approved in Europe to treat myocardial infarction, pulmonary embolism, unstable angina, and venous thrombosis. The pharmaceutical is active against antithrombin-III.
Trade Name Arixtra
Common Name Fondaparinux sodium
Indication myocardial infarction, pulmonary embolism, unstable angina, venous thrombosis
Drug Class Antithrombotyic indirect selective synthetic factor Xa inhibitors
Fondaparinux sodium
Get full access now